A medical technology company is to continue its fight against cancer after securing a new investment from a regional venture capital fund.

Vision RT, a developer of 3D surface imaging systems designed to improve the effectiveness of radiotherapy treatments, has received £250,000 from The Capital Fund, a venture capitalist that backs small businesses in London.

The new finance will allow the company to expand its business in the US, where it already has an office in Boston. It will also be used to develop and market its existing products, GateCT and GateRT.

The Capital Fund’s investment director, Ian Cameron, said the firm is investing in Vision RT at such an exciting stage of its development. “The new round of funding will allow the Vision RT team to take the company forward on an even more secure footing.”

Vision RT was founded in 2001 by chief executive Norman Smith, chief technology officer Ivan Meir and non-executive director Peter Kalms.

They established the company after identifying a need for better patient set-up and monitoring during radiotherapy treatments. Vision RT’s systems produce a three dimensional model of the patient that enables more accurate positioning of the stream of radiation so it is delivered direct to the tumour and avoids the surrounding tissue.

Vision RT’s systems are used in radiotherapy treatment centres such as Massachusetts General Hospital in Boston and London’s Royal Marsden Hospital.